Clin Med Insights Oncol
April 2017
Introduction: The identification of as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in mortality rates and accordingly an increase in the estimated prevalence of CML.
Case Report: Based on medical records and clinical follow-up, the authors present the case of a Philadelphia chromosome-positive CML patient who developed resistance to imatinib. Quantitative reverse transcription-polymerase chain reaction testing revealed a V280G mutation.